Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma.

Keyvan Nouri, Christopher O'Connell, Maria Patricia Rivas

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


Topical imiquimod is an immune response modifier FDA approved for the treatment of anogenital warts. Recent studies have reported its effectiveness in the treatment of some types of basal cell carcinomas. There have also been some case reports and case series reporting success treating of squamous cell carcinoma in situ with imiquimod. We report two patients with squamous cell carcinoma in situ and one with invasive squamous cell carcinoma treated with 5% imiquimod cream. Lesions were located on shin, posterior shoulder, and nasal tip. 5% imiquimod cream was applied at night for six weeks. Side effects included erythema and crusting in one patient. Biopsies taken four weeks after treatment revealed no residual squamous cell carcinoma in situ or squamous cell carcinoma. Topical 5% imiquimod cream is becoming established as a promising treatment for squamous cell carcinoma in situ. It also seems to be an alternative treatment for some cases of squamous cell carcinoma.

Original languageEnglish (US)
Pages (from-to)669-673
Number of pages5
JournalJournal of drugs in dermatology : JDD
Issue number6
StatePublished - Dec 2003

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma.'. Together they form a unique fingerprint.

Cite this